SAN DIEGO, May 16 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals, Inc. will be presenting at the Sixth Annual JMP Securities Research Conference on May 22, 2007, at 10:00 a.m. Pacific Daylight Time. Mike Grey, president and chief executive officer of SGX Pharmaceuticals, will provide an overview of the Company’s oncology pipeline. The conference is being held May 21 through 23 at the Ritz-Carlton in San Francisco.
A live webcast of the presentation will be available under the investor relations section of the Company’s website at www.sgxpharma.com. Replays of the presentation will be available for 90 days following the event. Please connect to the Company’s website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About SGX Pharmaceuticals
SGX Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of innovative cancer therapeutics. The SGX oncology pipeline includes drug candidates from its enabling, proprietary FAST(TM) drug discovery platform, such as next generation BCR-ABL inhibitors currently being developed in partnership with Novartis, MET tyrosine kinase inhibitors, including SGX523, and potent JAK2 inhibitors. More information on the pipeline and drug discovery platform can be found at www.sgxpharma.com and in the Company’s various filings with the Securities and Exchange Commission.
SGX Pharmaceuticals, Inc.
CONTACT: Todd Myers, Chief Financial Officer of SGX Pharmaceuticals, Inc.,+1-858-558-4850; or Jason Spark, Media & Investor Relations of PorterNovelli Life Sciences, +1-619-849-6005, for SGX Pharmaceuticals, Inc.
Web site: http://www.sgxpharma.com/
